Pet Meds, Librela and FDA

Pet Meds, Librela and FDA in Veterinarians: the news, the names and what changed.

  • 19 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Pet Meds, Librela and FDA


financialcontent.com > article > bizwire-2026-10-6-new-peer-reviewed-publication-on-laboratory-study-that-demonstrated-simparica-trio-protected-3x-more-dogs-from-infection-with-a-resistant-heartworm-isolate-than-nexgard-plus1

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

19+ hour, 40+ min ago   (173+ words) Head-to-Head Results At a Glance: Simparica Trio vs. NexGard Plus Against ML-Resistant Heartworm (ZoeLA Isolate)1 Dogs with adult heartworms at study end Average adult worm count Efficacy vs. untreated control Dogs testing positive for heartworm antigen at day 237 Dogs with…...


quiverquant.com > news > Endovia+Health+Sciences+Announces+FDA+Minor+Use+Determination+for+CannEpil%C2%AE+in+Dogs+With+Bone+Cancer+Pain

Endovia Health Sciences Announces FDA Minor Use Determination for CannEpil® in Dogs With Bone Cancer Pain

1+ day, 18+ hour ago   (431+ words) Endovia Health announces FDA classification of CannEpil® for bone cancer pain management in dogs, pursuing conditional approval. CannEpil® is an investigational oral solution for controlling pain associated with bone cancer in dogs. The minor use designation allows CannEpil® to pursue…...


biospace.com > press-releases > compass-pathways-launches-change-the-tune-in-trd-in-the-u-s-to-advance-hcp-understanding-of-treatment-resistant-depression-at-psych-congress-2026

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

3+ week, 15+ hour ago   (134+ words) Bringing the TRD conversation to Psych Congress Change the Tune in TRD will debut at Psych Congress 2026 through a three-panel Innovation Theater bringing together leaders in psychotherapy, general psychiatry, and interventional psychiatry to explore key topics in the understanding, identification…...